• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Expanding Ivonescimab Into First-Line Bladder Cancer Just Shift Summit Therapeutics' (SMMT) Investment Narrative?

    Simply Wall St·08/07/2026 21:34:58
    Listen to the news
    • Summit Therapeutics has expanded its global registration-enabling program for ivonescimab by initiating the HARMONi-GU1 Phase II/III trial in previously untreated locally advanced or metastatic urothelial (bladder) cancer, comparing ivonescimab plus enfortumab vedotin against the current standard pembrolizumab plus enfortumab vedotin.
    • This move adds bladder cancer to Summit’s growing list of tumor types for ivonescimab and further tests whether its bispecific PD-1/VEGF design can offer differentiated outcomes in a large, high-need cancer population.
    • We’ll now examine how launching the large, global HARMONi-GU1 trial in bladder cancer may influence Summit Therapeutics’ existing investment narrative.

    Find 49 companies with promising cash flow potential yet trading below their fair value.

    Summit Therapeutics Investment Narrative Recap

    To own Summit Therapeutics, you need to believe ivonescimab can become a commercially meaningful oncology platform across several major tumors, starting with lung cancer. The key near term catalyst remains the FDA’s HARMONi decision for EGFR‑mutant NSCLC, while the biggest risk is the company’s heavy spend and single‑drug dependence. The new HARMONi‑GU1 bladder cancer trial slightly broadens the story but does not change that near term risk reward focus in a material way.

    Among recent updates, the FDA’s acceptance of Summit’s Biologics License Application for ivonescimab in EGFR‑mutant NSCLC, with a US PDUFA date of November 14, 2026, is still the most relevant catalyst. The new HARMONi‑GU1 trial fits alongside this by reinforcing the long term multi tumor ambition for ivonescimab, but the regulatory outcome for HARMONi in lung cancer continues to anchor expectations for future revenue scale and funding capacity.

    Yet in contrast to that opportunity, investors should be aware that Summit is still loss making with quarterly operating expenses above US$100,000,000 and...

    Read the full narrative on Summit Therapeutics (it's free!)

    Summit Therapeutics’ narrative projects $897.3 million in revenue and $169.7 million in earnings by 2029. This implies an earnings increase of about $1.37 billion from -$1.2 billion today.

    Uncover how Summit Therapeutics' forecasts yield a $28.36 fair value, a 109% upside to its current price.

    Exploring Other Perspectives

    SMMT 1-Year Stock Price Chart
    SMMT 1-Year Stock Price Chart

    While consensus leans on broad ivonescimab potential, the most cautious analysts, who only projected about US$37,400,000 in revenue by 2029, worry that each new Phase III like HARMONi‑GU1 raises the bar for success and could stretch R&D spending further if results do not clearly stand out.

    Explore 4 other fair value estimates on Summit Therapeutics - why the stock might be worth over 5x more than the current price!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Summit Therapeutics?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.